Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.

× No keyword cloud information.

10 in total

Review 1. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Authors: Vishal Jindal; Ena Arora; Sorab Gupta
Journal: Med Oncol Date: 2018-05-05 Impact factor: 3.064

2. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

Authors: Soranobu Ninomiya; Neeharika Narala; Leslie Huye; Shigeki Yagyu; Barbara Savoldo; Gianpietro Dotti; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Carlos A Ramos
Journal: Blood Date: 2015-05-04 Impact factor: 22.113

3. (-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells.

Authors: Kengo Ogawa; Takeshi Hara; Masahito Shimizu; Junji Nagano; Tomohiko Ohno; Masato Hoshi; Hiroyasu Ito; Hisashi Tsurumi; Kuniaki Saito; Mitsuru Seishima; Hisataka Moriwaki
Journal: Oncol Lett Date: 2012-06-15 Impact factor: 2.967

4. Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.

Authors: Nobuhiko Nakamura; Takeshi Hara; Masahito Shimizu; Ryoko Mabuchi; Junji Nagano; Tomohiko Ohno; Takahiro Kochi; Masaya Kubota; Yohei Shirakami; Naoe Goto; Hiroyasu Ito; Kuniaki Saito; Takuji Tanaka; Hisataka Moriwaki; Hisashi Tsurumi
Journal: Int J Hematol Date: 2015-08-05 Impact factor: 2.490

Review 5. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.

Authors: Guangna Liu; Wei Rui; Xueqiang Zhao; Xin Lin
Journal: Cell Mol Immunol Date: 2021-03-30 Impact factor: 11.530

6. The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.

Authors: Yuhei Shibata; Takeshi Hara; Junji Nagano; Nobuhiko Nakamura; Tomohiko Ohno; Soranobu Ninomiya; Hiroyasu Ito; Takuji Tanaka; Kuniaki Saito; Mitsuru Seishima; Masahito Shimizu; Hisataka Moriwaki; Hisashi Tsurumi
Journal: PLoS One Date: 2016-01-04 Impact factor: 3.240

7. Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.

Authors: A Marijne Heeren; Ilse van Dijk; Daniella R A I Berry; Maryam Khelil; Debbie Ferns; Jeroen Kole; René J P Musters; Victor L Thijssen; Constantijne H Mom; Gemma G Kenter; Maaike C G Bleeker; Tanja D de Gruijl; Ekaterina S Jordanova
Journal: Front Immunol Date: 2018-07-11 Impact factor: 7.561

8. Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation.

Authors: Claudio Giacinto Atene; Stefania Fiorcari; Nicolò Mesini; Silvia Alboni; Silvia Martinelli; Monica Maccaferri; Giovanna Leonardi; Leonardo Potenza; Mario Luppi; Rossana Maffei; Roberto Marasca
Journal: Front Immunol Date: 2022-03-18 Impact factor: 7.561

9. IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma.

Authors: Chengtao Sun; Mengzhen Li; Lian Zhang; Feifei Sun; Huimou Chen; Yanjie Xu; Yingxia Lan; Li Zhang; Suying Lu; Jia Zhu; Junting Huang; Juan Wang; Yang Hu; Yanfen Feng; Yizhuo Zhang
Journal: Cell Death Dis Date: 2022-06-27 Impact factor: 9.685

10. Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience.

Authors: Mee-Seon Kim; Tae In Park; Shin-Ah Son; Hyoun Wook Lee
Journal: Diagnostics (Basel) Date: 2020-05-02

10 in total